Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 15/20 | 0.52 |
| ▸ | HTR2C | P28335 | 14/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13978314 | 0.84 | HTR2A (0.53) | HTR2AHTR2CMAPKAPK2 | |
| SCHEMBL5421567 | 0.83 | S1PR1 (0.59) | MAPKAPK2BRD3 | |
| SCHEMBL5088953 | 0.83 | S1PR1 (0.59) | MAPKAPK2BRD3 | |
| SCHEMBL30762338 | 0.83 | S1PR1 (0.59) | MAPKAPK2BRD3 | |
| SCHEMBL29141416 | 0.83 | S1PR1 (0.59) | MAPKAPK2BRD3 | |
| SCHEMBL4104217 | 0.82 | HTR2A (0.62) | HTR2AHTR2CMAPKAPK2BRD3HTR2B | |
| SCHEMBL4105569 | 0.77 | KMT2A (0.52) | HTR2AHTR2CMAPKAPK2BRD3HTR2B | |
| SCHEMBL9019672 | 0.76 | BRD3 (0.60) | MAPKAPK2BRD3 | |
| SCHEMBL6692543 | 0.75 | S1PR1 (0.53) | HTR2AHTR2CMAPKAPK2BRD3 | |
| SCHEMBL28503828 | 0.75 | BRD3 (0.58) | HTR2AHTR2CMAPKAPK2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115921-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20100081696-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | BERTHELETTE CARL | 2010-04-01 | — | — | US | disclosed |
| US-7618994-B2 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | MERCK FROSST CANADA LTD. (CA) | 2009-11-17 | — | — | US | disclosed |
| US-20090233977-A1 | Method of Treating Atherosclerosis, dyslipidemias and related conditions | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20080033028-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | BERTHELETTE CARL | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115921-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | PTGER1, PTGER3, PTGER2 | HTR2A 310/4885HTR2C 317/4885MAPKAPK2 2712/4885 |
| US-20080033028-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | PTGER1, PTGER3, PTGER2 | HTR2A 310/4885HTR2C 317/4885MAPKAPK2 2712/4885 |
| US-20090233977-A1 | Method of Treating Atherosclerosis, dyslipidemias and related conditions | LDLR, HCAR1, FFAR1 | HTR2A 732/4885HTR2C 1937/4885MAPKAPK2 2091/4885 |
| US-20100081696-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | PTGER1, PTGER3, PTGER2 | HTR2A 310/4885HTR2C 317/4885MAPKAPK2 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.